Given the current complexities of the Medicaid, Children's Health Insurance Program (CHIP), and Basic Health Program enrollment processes, AMCP submitted comments in response to a September 7 Notice of Proposed Rulemaking (NPRM) from the Centers for Medicare and Medicaid Services (CMS). Dated November 4, AMCP's comments support the NPRM's proposed goal to simplify the enrollment process for these vital health programs. The comments specifically address the cycle of enrollment and disenrollment that program beneficiaries face, often referred to as “eligibility churn."
The Centers for Medicare and Medicaid Services (CMS) unveiled a Request for Information (RFI) titled "Make Your Voice Heard" on September 6. The RFI sought public input on healthcare accessibility, understanding provider experiences, advancing health equity, and assessing the impact of waivers and flexibilities provided in response to the COVID-19 Public Health Emergency. On November 4, AMCP responded with a comment letter offering insights into challenges related to access to medication. The comments also offer recommendations for advancing health equity within CMS.
In this corporate member spotlight, Senior Director of National Accounts for Servier, Cher Mitchell, PharmD, MBA, MPH, discusses why her company chose to partner with AMCP as a corporate member.
October 2022 Legislative & Regulatory Briefing; Tell Congress to Pass the PIE Act!; Member Benefit! Regulatory NewsBREAKS; Managed Care Practitioners Receive Legislative, Regulatory, and Midterm Updates at AMCP Nexus 2022; AMCP CEO Susan Cantrell Pens Op-Ed in Support of PIE Legislation; AMCP Responds to NPRM on Nondiscrimination in Health Programs and Activities; FDA Awards $1.3 Million Grant to BBCIC.
Today, the Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) announced that it has received a major grant from the Food & Drug Administration (FDA) in support of biosimilars research. The award provides $1.3 million over two years for a new BBCIC study focused on increasing the efficiency of biosimilar drug development and review.
On August 4, the Department of Health and Human Services released a Notice of Proposed Rulemaking on Nondiscrimination in Health Programs and Activities. In response, AMCP submitted comments on September 29 which applaud the Department's goal to reinstate regulatory protections from discrimination in covered health programs and activities.